Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia / Singh, Abhishek A.; Petraglia, Francesca; Nebbioso, Angela; Yi, Guoqiang; Conte, Mariarosaria; Valente, Sergio; Mandoli, Amit; Scisciola, Lucia; Lindeboom, Rik; Kerstens, Hinri; Janssen-Megens, Eva M.; Pourfarzad, Farzin; Habibi, Ehsan; Berentsen, Kim; Kim, Bowon; Logie, Colin; Heath, Simon; Wierenga, Albertus T. J.; Clarke, Laura; Flicek, Paul; Jansen, Joop H.; Kuijpers, Taco; Yaspo, Marie Laure; Della Valle, Veronique; Bernard, Olivier; Gut, Ivo; Vellenga, Edo; Stunnenberg, Hendrik G.; Mai, Antonello; Altucci, Lucia; Martens, Joost H. A.. - In: ONCOTARGET. - ISSN 1949-2553. - 9:39(2018), pp. 25647-25660. [10.18632/oncotarget.25429]
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia
Valente, Sergio;Mai, Antonello;
2018
Abstract
Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.| File | Dimensione | Formato | |
|---|---|---|---|
|
Singh_Multi-omics_2018.pdf
accesso aperto
Note: L'articolo riporta: "This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited".
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
3.82 MB
Formato
Adobe PDF
|
3.82 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
